NEW YORK (GenomeWeb) – Nanopore-based sequencing firm Quantapore today announced it closed a Series B financing round raising up to $35 million.

The Menlo Park, Calif.-based firm did not disclose the name of the investors but said that the funds will go toward finalizing the development of its sequencing technology and commercializing its platform.

The final amount of the raise will depend on whether Quantapore meets certain milestones before all funds are released, Quantapore CEO Martin Huber said in an email.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.